MTOR and diabetic kidney disease: Inhibition of EGFR with erlotinib attenuated the development of diabetic nephropathy in type 1 diabetes, which was mediated at least in part by inhibition of mTOR and activation of AMPK, with increased autophagy and inhibition of ER stress